- In April 2024, Micro-Tech (Nanjing) Co., Ltd. launched its next-generation self-expanding metallic airway stent designed to reduce migration and enhance patient comfort. The product incorporates an advanced anti-migration design and improved radial force, reflecting the company’s continued focus on innovation in interventional pulmonology and its commitment to improving clinical outcomes in complex airway management cases. This launch reinforces Micro-Tech's role as a global leader in minimally invasive therapeutic devices
- In March 2024, Boston Scientific Corporation announced the initiation of a multicenter clinical trial to evaluate the safety and efficacy of its new drug-eluting tracheobronchial stent for treating malignant central airway obstructions. This development aims to address complications such as restenosis and inflammation by combining mechanical support with localized drug delivery. The trial marks a significant step forward in integrating pharmaceutical and device-based therapy in respiratory care
- In February 2024, Novatech SA introduced a customizable silicone stent series tailored for pediatric airway interventions. Designed for improved biocompatibility and ease of placement, the product launch responds to the growing demand for specialized stenting solutions for younger patients with congenital or acquired airway anomalies. This advancement demonstrates Novatech’s commitment to addressing unmet needs in pediatric interventional pulmonology
- In January 2024, Merit Medical Systems, Inc. announced the expansion of its Endotek division’s manufacturing capabilities, specifically to scale up production of its hybrid tracheobronchial stents. The investment includes advanced material processing technologies aimed at improving stent precision, durability, and patient tolerance. This move supports Merit’s strategic goal to meet rising global demand for high-quality, minimally invasive pulmonary devices
- In December 2023, Taewoong Medical Co., Ltd. received CE Mark approval for its newly developed biodegradable airway stent. Designed to offer temporary support in benign airway strictures, the stent gradually dissolves after fulfilling its therapeutic purpose, minimizing the need for stent removal procedures. This regulatory milestone enhances Taewoong’s footprint in the European market and underscores the industry's growing interest in bioresorbable stenting technologies
